查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1751189

北美外用藥物 CDMO 市場規模、佔有率、趨勢分析報告：按產品、服務、最終用途、國家、細分市場預測，2025 年至 2030 年

North America Topical Drugs CDMO Market Size, Share & Trends Analysis Report By Product (Semi-solid, Liquid), By Service (Contract Development, Contract Manufacturing), By End Use, By Country, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

北美外用藥物 CDMO 市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，北美外用藥物CDMO市場規模預計到2030年將達到272.2億美元，2025年至2030年的複合年成長率為10.88%。

研發投入的不斷增加，以及對多種皮膚病新型治療藥物的需求不斷成長，推動了外用藥物CDMO市場的需求不斷成長。由於使用方便、副作用小，消費者對多種外用溶液的偏好日益成長，也是市場成長的促進因素。

對創新和新產品開發日益成長的需求預計將改善市場需求，而競爭壓力和價格擔憂正促使企業將開發新藥和生產外包。預計這將推動整體市場成長。此外，CDMO正在利用奈米技術等先進技術在分子層面上操縱藥物顆粒，以提高藥物穩定性和生物有效性。此外，微膠囊技術透過保護精細成分並實現控制釋放和標靶藥物傳遞來提高治療效果。這些技術進步正在加速北美市場的成長潛力。

該CDMO積極與製藥公司合作，並就創新藥物開發和多種外用藥物製劑的生產達成長期協議。例如，2023年1月，專注於皮膚外用藥物的知名供應商－瑞士-美國CDMO與EveryDrop分配平台的發明者LiquiGlide達成合作。透過此次合作，該公司將利用LiquiGlide創新、無毒、光滑的表面技術，消除液體和固體之間的摩擦，從而減少消費包裝產品中的產品廢棄物。

北美外用藥物CDMO市場報告重點：

  • 根據產品類型，半固態劑型預計將在 2024 年佔據市場主導地位，收入佔有率超過 66.47%。這是由於其具有許多優勢，例如易於給藥，以及由於多種副作用，患者更喜歡外用藥物而不是口服藥物，這預計將推動對該領域的需求。
  • 根據服務類型，契約製造部門預計在預測期內將以顯著的複合年成長率成長。
  • 按贊助商分類，製藥公司將在 2024 年佔據最大的市場佔有率。製藥公司對開發和商業化創新外用藥物的研發投資的發展預計將推動市場收益的成長。
  • 由於該地區市場參與企業強大、政府對優質醫療保健的支持以及對化妝品的高需求，美國在北美外用 CDMO 行業中佔據主導地位。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 北美外用藥物 CDMO 市場變數、趨勢與範圍

  • 市場展望
    • 母市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 定價分析
  • 外用藥物CDMO產能展望
    • CDMO生產貨櫃容量
    • 外用藥容器容量（產品類型）
  • 北美外用藥物CDMO市場展望（依產品類型）
    • 2024 年北美外用藥物 CDMO市場佔有率（依產品類型分類）(%)
    • 處方藥
    • 學名藥
    • 非處方藥
  • 北美外用藥物CDMO市場分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19影響分析
    • 美國關稅影響分析

第4章北美外用藥物CDMO市場：產品預估與趨勢分析

  • 2024年及2030年的產品市場佔有率
  • 細分儀表板
  • 北美外用藥物CDMO市場：產品展望
  • 2018年至2030年市場規模、預測及趨勢分析
    • 半固態製劑
    • 液體製劑
    • 固態製劑
    • 經皮產品

第5章北美外用藥物CDMO市場：服務估算與趨勢分析

  • 2024年及2030年服務市場佔有率
  • 細分儀表板
  • 北美外用藥物 CDMO 市場：服務展望
  • 2018年至2030年市場規模、預測及趨勢分析
    • 合約開發
    • 契約製造

6. 北美外用藥物CDMO市場：最終用途預估及趨勢分析

  • 2024 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 北美外用藥物 CDMO 市場：依最終用途展望
  • 2018年至2030年市場規模、預測及趨勢分析
    • 製藥公司
    • 生物製藥公司
    • 其他

第7章 北美外用藥物 CDMO 市場：各國估值及趨勢分析

  • 2024 年及 2030 年各國市場
  • 各國市場儀表板
  • 各國市場
  • 2018-2030年市場規模、預測與趨勢分析
  • 美國
    • 主要國家趨勢
    • 競爭場景
    • 法律規範
  • 加拿大
    • 主要國家趨勢
    • 競爭場景
    • 法律規範
  • 墨西哥
    • 主要國家趨勢
    • 競爭場景
    • 法律規範

第8章 競爭態勢

  • 公司/競爭對手分類
    • 市場領導者
    • 新興企業
  • 2024 年公司市場佔有率/估值分析
  • 公司簡介
    • The Lubrizol Corporation
    • Cambrex Corporation
    • Contract Pharmaceuticals Limited
    • Bora Pharmaceutical CDMO
    • Ascendia Pharmaceuticals
    • Pierre Fabre SA
    • Piramal Pharma Solutions
    • DPT Laboratories, LTD.
    • MedPharm Ltd.
    • Zenvisionpharma
Product Code: GVR-4-68040-188-4

North America Topical Drugs CDMO Market Growth & Trends:

The North America topical drugs CDMO market size is anticipated to reach USD 27.22 billion by 2030, registering a CAGR of 10.88% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing investment in R&D activities coupled with rising need for novel therapeutics for several dermatological conditions contributes to the growing demand for topical drugs CDMO market. Rising consumer preference for several topical solutions owing to ease of administration and minimized side effects are other factors supporting the growth of the market.

The growing need for novel innovation and new product developments are expected to improve the demand in the market, and competitive pressure & pricing concerns are driving companies to outsource new drug development & manufacturing. This is expected to drive overall market growth. Moreover, CDMOs are leveraging several advanced technologies such as nanotechnology to manipulate drug particles at the molecular level, enhancing drug stability and bioavailability. Moreover, microencapsulation techniques protect sensitive ingredients, allowing for controlled release and targeted drug delivery, amplifying therapeutic outcomes. Such technological advancements are accelerating market growth potential in North America.

CDMOs are actively involved in collaboration & partnerships with pharmaceutical companies to secure long-term contracts for innovative drug development and manufacturing of several topical formulations, which is expected to spur market demand. For instance, in January 2023, Swiss-American CDMO, a prominent provider specializing in topical skin care products, collaborated with LiquiGlide, the inventor of the EveryDrop dispensing platform. Through this collaboration, the company will utilize LiquiGlide's innovative nontoxic slippery surface technology to eliminate friction between liquids & solids and product waste for consumer-packaged goods.

North America Topical Drugs CDMO Market Report Highlights:

  • Based on product type, the semi-solid formulations segment dominated the market with a revenue share of more than 66.47% share in 2024, owing to numerous advantages including ease of administration and patient preference for topical drugs compared to the oral route of administration owing to several adverse effects, which is expected to drive segment demand
  • Based on service type, the contract manufacturing segment is expected to grow at the substantial CAGR over the forecast period
  • Based on sponsors, the pharmaceutical companies segment held the largest market share in 2024. Growing R&D investments by several pharmaceutical companies to develop and commercialize innovative topical drugs is anticipated to boost market revenue growth
  • The U.S. dominated the North America topical drugs CDMO industry owing to factors such as strong presence of market participants in the region, government support for quality healthcare and high demand for cosmetic products

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Parent Market Analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Topical Drugs CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Technological advancements & growing R&D investments
      • 3.2.1.2. Rising demand for topical medications
      • 3.2.1.3. Expansion of manufacturing capacities and partnerships
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance with strict regulatory requirements
      • 3.2.2.2. Limited efficacy in certain conditions limits the adoption of topical products
  • 3.3. Pricing Analysis
  • 3.4. Topical Drugs CDMO Capacity Outlook
    • 3.4.1. CDMO Manufacturing Container Capacity
    • 3.4.2. Topical Drugs Container Capacity By Product Type
  • 3.5. North America Topical Drugs CDMO Market Outlook By Product Category
    • 3.5.1. North America Topical Drugs CDMO Market Share, By Product Category, 2024 (%)
    • 3.5.2. Prescription Drugs
      • 3.5.2.1. Segment Overview
      • 3.5.2.2. Major Prescription Drugs, By Product Type
    • 3.5.3. Generic Drugs
      • 3.5.3.1. Segment Overview
      • 3.5.3.2. Major Generic Drugs, By Product Type
    • 3.5.4. Over-the-counter (OTC) Drugs
      • 3.5.4.1. Segment Overview
      • 3.5.4.2. Major OTC Drugs, By Product Type
  • 3.6. North America Topical Drugs CDMO Market Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis
    • 3.6.4. U.S. Tariff Impact Analysis

Chapter 4. North America Topical Drugs CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. North America Topical Drugs CDMO Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Semi-solid Formulations
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Creams
        • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Ointments
        • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Lotions
        • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Others
        • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Liquid Formulations
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Suspensions
        • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Solutions
        • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Solid Formulations
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Transdermal Products
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. North America Topical Drugs CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Service Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. North America Topical Drugs CDMO Market by Service Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Contract Development
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Formulation Development
        • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Analytical Testing
        • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.4. Stability Testing
        • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.5. Others
        • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Contract Manufacturing
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Clinical
        • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3. Commercial
        • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. North America Topical Drugs CDMO Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. North America Topical Drugs CDMO Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Pharmaceutical Companies
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Biopharmaceutical Companies
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. North America Topical Drugs CDMO Market: Country Estimates & Trend Analysis

  • 7.1. Country Market Share Analysis, 2024 & 2030
  • 7.2. Country Market Dashboard
  • 7.3. Country Market Snapshot
  • 7.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030
  • 7.5. U.S.
    • 7.5.1. Key country dynamics
    • 7.5.2. Competitive scenario
    • 7.5.3. Regulatory framework
    • 7.5.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Canada
    • 7.6.1. Key country dynamics
    • 7.6.2. Competitive scenario
    • 7.6.3. Regulatory framework
    • 7.6.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Mexico
    • 7.7.1. Key country dynamics
    • 7.7.2. Competitive scenario
    • 7.7.3. Regulatory framework
    • 7.7.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Company Market Share/Assessment Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. The Lubrizol Corporation
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Product/service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Cambrex Corporation
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product/service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Contract Pharmaceuticals Limited
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product/service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Bora Pharmaceutical CDMO
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product/service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Ascendia Pharmaceuticals
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product/service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Pierre Fabre S.A.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product/service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Piramal Pharma Solutions
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product/service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. DPT Laboratories, LTD.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product/service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. MedPharm Ltd.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product/service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Zenvisionpharma
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product/service benchmarking
      • 8.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global topical drugs CDMO: market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Table 4 Global topical drugs: market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Table 5 Development stages baseline model parameter estimates, By topical drugs
  • Table 6 Global topical drugs CDMO manufacturing container capacity/batch
  • Table 7 Global topical drugs capacity, by product type (per unit)
  • Table 8 Global topical drugs capacity, by container type (per unit)
  • Table 9 North America topical drugs CDMO market share, by product category, 2024 (%)
  • Table 10 List of major prescription drugs, by product type (2024)
  • Table 11 List of major generic drugs, by product type (2024)
  • Table 12 List of major OTC drugs, by product type (2024)
  • Table 13 North America topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 14 North America topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 15 North America topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
  • Table 16 North America topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 17 North America topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
  • Table 18 North America topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 19 North America topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 20 North America topical drugs CDMO market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 21 U.S. topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 22 U.S. topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 23 U.S. topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
  • Table 24 U.S. topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 25 U.S. topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
  • Table 26 U.S. topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 27 U.S. topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 28 Canada topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 29 Canada topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 30 Canada topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
  • Table 31 Canada topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 32 Canada topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
  • Table 33 Canada topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 34 Canada topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 35 Mexico topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 36 Mexico topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 37 Mexico topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
  • Table 38 Mexico topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 39 Mexico topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
  • Table 40 Mexico topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 41 Mexico topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 42 Company profiles: Company overview
  • Table 43 Company profiles: Financial performance
  • Table 44 Company profiles: Service benchmarking
  • Table 45 Key company initiating service launches/upgrades
  • Table 46 Key companies initiating mergers/acquisitions/joint ventures
  • Table 47 Key companies initiating partnerships
  • Table 48 Key companies initiating expansion
  • Table 49 Key companies initiating others

List of Figures

  • Fig. 1 North America topical drugs CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Global topical drugs CDMO market outlook, 2023 (USD Billion)
  • Fig. 13 Global topical drugs market outlook, 2023 (USD Billion)
  • Fig. 14 North America topical drugs CDMO market dynamics
  • Fig. 15 Porter's Five Forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 North America Topical Drugs CDMO market: Product Type outlook and key takeaways
  • Fig. 18 North America Topical Drugs CDMO market: Product Type movement analysis
  • Fig. 19 Semi-solid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Creams market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Ointments market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Lotions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Liquid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Suspensions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Solutions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Solid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Transdermal products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 North America Topical Drugs CDMO market: Service type outlook and key takeaways
  • Fig. 30 North America Topical Drugs CDMO market: Service type movement analysis
  • Fig. 31 Contract development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Formulation development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Analytical testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Stability testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Commercial market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 North America Topical Drugs CDMO market: sponsors outlook and key takeaways
  • Fig. 40 North America Topical Drugs CDMO market: sponsors movement analysis
  • Fig. 41 Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 North America Topical Drugs CDMO market revenue, by country, 2023 & 2030 (USD Million)
  • Fig. 45 Regional outlook, 2023 & 2030
  • Fig. 46 Regional Market Share Analysis, 2023 & 2030
  • Fig. 47 North America Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 48 Key country dynamics
  • Fig. 49 U.S. Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Canada Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 52 Market participant categorization
  • Fig. 53 Market participant categorization
  • Fig. 54 Heat map analysis